Editorial
Georgios Kallifatidis
Abstract
Over expression of chemokine receptors such as CXCR7 is a common hallmark of various cancers. Recent evidence suggests that CXCR7 interacts with the epidermal growth factor receptor (EGFR) to activate downstream mitogenic signaling and proliferation in tumour cells. Few current therapies directly target CXCR7; however, targeting the interaction between CXCR7 and EGFR might be a promising therapeutic strategy to inhibit proliferation in cancer cells.